A targeted medicine for selected acute myeloid leukemia with an IDH2 mutation.
Profile scope: Enasidenib. Confirm the exact product and route; formulations and combination products are not interchangeable.
Possible side effects
Nausea, vomiting, diarrhea, appetite reduction and taste changes may occur.
Serious risks and warning signs
Life-threatening differentiation syndrome can cause fever, rapid weight gain, swelling, reduced urine and breathing difficulty. These symptoms need immediate oncology assessment. Jaundice, abnormal heartbeat, muscle spasms or seizures also require urgent review.
A question for your healthcare team
How will I recognize differentiation syndrome, and what is the around-the-clock contact plan if symptoms appear?
What to do with this information
Discuss persistent or troubling symptoms with your prescriber or pharmacist. For severe breathing difficulty, collapse, a seizure, or inability to wake someone, seek emergency help. Read the linked medicine information for drug-specific instructions, including situations requiring immediate action. For routine treatment changes, consult your prescriber rather than changing your dose on your own. Follow the urgent action instructions above and in the linked medicine information.
Sources
Sources checked November 20, 2026. An original AI-assisted educational summary, not a complete adverse-effect or interaction list. This profile is part of the broader library expansion, not the original prescription-use ranking. Inclusion does not confirm current product availability or mean that risks outweigh benefits. This page has not been independently reviewed by a clinician.